An analysis of the effects of using the B-mode ultrasound Acquisition and Targeting (BAT) system for positioning of prostate cancer patients receiving external beam radiotherapy (EBRT) on late gastrointestinal (GI) and genitourinary (GU) toxicity is provided. The records of 49 consecutive patients treated using the BAT were reviewed; additionally, a comparison (No-BAT) group treated in a similar manner was identified, consisting of 49 patients treated immediately prior to this BAT group. There were no other fundamental differences between the two groups. The daily BAT movements were charted and late toxicity was scored for all patients using established toxicity scales. The results demonstrated similar GU toxicity rates between the two groups, but slightly lower rates of GI toxicity in the BAT group vs. the No-BAT group. However, regression analyses revealed that no factors, including BAT use, were significantly correlated with late GI or GU toxicity. Further efforts, perhaps better undertaken in a multi-institutional setting, are needed to determine whether BAT use can significantly reduce late GI toxicity.
Introduction
Prostate cancer is among the most common malignancies for which medical intervention is undertaken (1, 2). High rates of biochemical control have been documented with many modalities, including external beam radiotherapy (EBRT) (3). Thus, one of the key features driving the decisions of both patients and physicians on treatment options is the level of expected side effects. Reduction of toxicity has been a key objective of many efforts related to radiotherapy. Within the context of EBRT, the evolution of conformal radiotherapy (4) to intensity modulated radiotherapy (IMRT) (5, 6) has been motivated in part by the desire to reduce toxicity, in many cases in parallel with efforts to escalate radiation dose.
These advances in the treatment planning process, even if the dose distributions designed are ideal at the time of the treatment planning session, may be only in part effective if other treatment factors, particularly daily treatment setup error and organ motion, are not accounted for (7) . The prostate has become the model site for advancements in understanding organ motion, as the position of the prostate is sensitive to filling of the surrounding rectum and bladder (8). Several approaches for accommodating this organ motion have been attempted. Among them are adaptive radiotherapy (9), the use of fiducial seeds (10) (11) (12) (13) (14) , the use of a rectal balloon (15), and, most relevant to the current investigation, transabdominal ultrasound (performed in this investigation as well as most oth-ers with the B-mode ultrasound Acquisition and Targeting (BAT) system) (16-26) (Nomos Corp., Sewickley, PA) to track the prostate on a daily basis.
Prior work on the BAT has been related to analyzing and validating the organ motion tracking accuracy and resulting guidelines on target volume expansion for treatment planning; some prior studies have also examined some of the potential shortcomings of the BAT system. The use of BAT has additionally been used in the context of IMRT and hypofractionation. These prior studies have shed light on the promising role of the BAT in accounting for organ motion. Although several studies suggest that the BAT may potentially serve an instrumental role in tracking the prostate on a daily basis, other studies have suggested that the BAT may not be reliable for patient positioning (21) and may actually introduce a small systematic error (26).
Although organ motion studies using the BAT have been reported, toxicity analyses with use of the BAT, are, in contrary, only in their preliminary stages of development. A preliminary report by our group (27) has explored the impact of the BAT on acute gastrointestinal (GI) and genitourinary (GU) toxicity -this report found that acute GU toxicity was not reduced but that acute GI toxicity was significantly reduced; furthermore, BAT use was the only factor that significantly predicted for this acute GI toxicity reduction. Because early and late radiation effects on normal tissues can be different (28-29), though, these early toxicity findings cannot be assumed to correlate with late toxicity. This is because normal tissues can have both early-responding and late-responding components, each with their own alpha/beta ratios (28); thus early and late responses can be uncorrelated, and the analysis of chronic toxicity requires its own separate analysis. To date, however, an analysis of the impact of BAT use in influencing late toxicity outcomes has not been reported when considering an appropriate comparison group in which the BAT was not used. In this work, we wish to analyze the impact of using the BAT for positioning of prostate cancer patients receiving external beam radiotherapy (RT) on late GI and GU toxicity.
Material and Methods
The records of consecutive prostate cancer patients seen by one physician (ABJ) in our department prior to December 2003 treated with EBRT and for whom late toxicity information was available were reviewed. Patients having brachytherapy boost after short-course (typically 45 Gy) EBRT were excluded to permit adequate EBRT dose for toxicity analysis (it was felt that a shorter dose of EBRT would artifactually lower the rates of toxicity if fewer weeks of RT were delivered). Patients receiving whole pelvis treatment were also excluded, as at our institution the BAT is only used on these patients for the non-whole-pelvis portion of treatment.
A group treated using the BAT from April 2003 (when the BAT was first installed at our institution) through December 2003 was identified and consisted of 49 patients. The BAT was used for daily setup for these patients. Additionally, a comparison (no-BAT) group treated with RT in a similar manner was identified, consisting of 49 patients treated during the 8 month period immediately prior to the BAT group. The general characteristics of these two groups are shown in Table I . As shown in this Table, there were no fundamental differences between the groups with regard to demographics, pathologic characteristics, treatment technique, and radiation dose.
Standard bowel preparation instructions were given to each patient, and, on the morning of the CT planning scan, the patient was asked to perform an enema. The patients were simulated and treated in the supine position. In order to immobilize the patient, customized upper and lower alpha cradles (Smithers Medical Products, Hudson, OH) were fabricated. A retrograde urethrogram was performed, and bladder contrast was used. Following the placement of a rectal tube, rectal contrast was injected. No intravenous contrast was used. A planning CT scan was performed in the treatment position using a flat table insert on an AcQSim CT-simulator (Philips Medical Systems, Cleveland, OH). The table   116 Jani et al. For each patient, the prostate and seminal vesicles were contoured. Also, the bladder and rectum were contoured on all patients according to RTOG criteria (30) -namely, the whole bladder was contoured and the rectum from the rectosigmoid junction to the ischial tuberosities was contoured. The margins of expansion to define the planning target volumes (PTV's) were identical for both groups and were as follows: PTV1 = (prostate+SV) + 1.0 cm and PTV2 = prostate + 1.0 cm (except for the posterior margin, which was 0.6 cm). PTV1 was treated to 50.0 Gy in 2.0 Gy fractions or 50.4 Gy in 1.8 Gy fractions, and PTV2 was treated to either 24 Gy in 2 Gy fractions (favorable prognosis patients) or 26 Gy in 2 Gy fractions (intermediate or poor-prognosis patients). Thus, a final dose of 74.0-76.4 was planned, with a nearly identical final dose prescribed in both groups, as shown in Table I .
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All patients were planned using the Corvus inverse planning system (Nomos Corp., Sewickley, PA). Prescription to the target volume was the same, as were the general constraints entered on the bladder and rectum. Additionally, dose was prescribed to a minimum target volume, with the same constraints and dose volume histogram criteria for acceptance of treatment plans. 5-or, more commonly, 7-field coplanar beams were used in all cases. Although there was no major treatment planning differences identifiable between the BAT and No-BAT groups, we felt that a more stringent technique to ensure that the treatment planning was balanced between the two groups was necessary. Thus, on all patients the volume of bladder and rectum receiving > 70 Gy (V 70 ) of the bladder and rectum were charted and are also shown in Table I ; as displayed, there was a slight difference in these parameters between the BAT and No-BAT groups, due perhaps to subtle changes in the treatment planning process over the study interval. Thus, bladder V 70 and rectum V 70 were included with BAT use and several other factors on regression analysis, as described below.
The BAT patients were given instructions to maintain a full bladder during treatment. In this group, the BAT system was used daily. All prostate patients, both in the BAT and no-BAT group, were treated using a Varian 2100EX linear accelerator (Varian Medical Systems, Palo Alto, CA). Furthermore, the same radiation therapists delivered the daily treatment and used the BAT on a daily basis; as a consequence, inter-observer variability in treatment setup and in BAT use was minimal. For the BAT group, daily movements were reviewed; a total of 4341 measurements [1447 in each of the three principal directions (Right-Left, UpDown, and In-Out)] were available.
Late toxicity during treatment was reviewed and available for all of these patients, and scores according to Radiation Therapy Oncology Group (RTOG) GI and GU toxicity scales (31) were assigned. For quality assurance, the toxicity scores for each patient were verified independently by two observers (ABJ and JG). The late toxicities in the BAT and no-BAT groups were tabulated. The movements (means and standard deviations) in each of the three principal directions were analyzed for correlation with late GI and GU toxicity by computing Pearson product moment correlation coefficients (32-33). The expectation was that with proper use of the BAT, the toxicity would be uncorrelated with the means or variations in the moves. As a further step, an ordered logit regression (considering late toxicity as an ordinal variable) of the impact of demographic, pathologic, and treatment factors (all factors were entered into the model simultaneously) on late GI toxicity and late GU toxicity was undertaken (32-33).
Results
Table II displays the observed rates of Grade 0-3 GU and GI toxicity (no Grade 4 or 5 toxicity was seen in any group). As displayed, in general the event rates toxicity, particularly grade 1-2 GI toxicity were quite low in both BAT and no-BAT groups.
Table III displays the means and standard deviations of the BAT moves in each of the three principal directions. The means deviate from 0.0, likely due to small systematic differences in laser position and/or rectal and bladder filling from the time of simulation. These means/standard deviations are similar to those of other reports (16-26). The correlation coefficients, computed in the manner described in the Methods section above, are displayed in Table III as well. Because these correlation coefficients were small (absolute value < 0.4) in all cases, the GU and GI toxicity can be interpreted as being generally uncorrelated with the directions or sizes of the BAT moves, an expected result with proper daily use of the BAT.
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Discussion
The importance of daily prostate positioning during EBRT is increasingly important in the context of dose escalation efforts and in the context of minimizing treatment toxicity. Although several investigations have analyzed and validated organ motion accuracy and suggested guidelines on target volume expansion, the current investigation is the first of its kind critically analyzing late toxicity with the use of the BAT system when considering a comparison group in which the BAT was not used.
The current results suggest that the BAT system did not change the rate of late GU toxicity. In looking at the absolute rates of GU toxicity in Table III , it is unlikely that the lack of statistical difference is due to power limitations of the study. One possible explanation for the findings is that urethral dose rather than proper alignment of the bladder/ prostate interface is a predominant factor in determining GU toxicity. At our institution we do not specifically constrain the urethral dose for EBRT patients, and urethral dose is likely to be similar in the BAT and no-BAT arms, even with proper daily use of the BAT.
Acute GI toxicity was, however, slightly lower in the BAT group, although the rates of GI toxicity, particularly grade 1-2 GI toxicity, were quite low in both groups. One interpretation for this finding is that this reduction in GI toxicity is due to reduction in integral rectal dose made possible by more accurate daily positioning. However, caution is warranted in attributing the reduction in late GI toxicity to BAT use for two reasons: (i) although integral rectal dose may be reduced with daily BAT use (indeed, as acute toxicity is highly correlated with integral dose, BAT use was found in a prior study (26) to be the only independent factor decreasing acute GI toxicity), late GI toxicity may be better correlated with percent volume of the rectum receiving a high dose (> 70 Gy); with proper daily use of the BAT, a higher volume of the rectum (particularly the anterior rectal wall) may receive a high dose than without BAT use, and biologically these two effects (lower rectal integral dose but higher rectal volume receiving high dose) are competing forces, so BAT use may or may not be expected to be a significant independent prognostic factor for reducing late GI toxicity, and (ii) as Table IV shows, the BAT did not reach significance in the regression analysis of factors predicting late GI toxicity; this may be due in part to other factors (such as improvements in the treatment planning and consequent reduction in rectum and bladder V 70 in the BAT group, although these variables were entered in the regression analysis and not found to reach significance either) and due the low event rate of late toxicity and consequent statistical limitations.
One alternative explanation of the results of the GU and GI toxicity analyses (which showed that the BAT was not an independent factor predicting for either type of late toxicity) is that the BAT may, as suggested by some studies (21, 26), introduce a small systematic error. This viewpoint may be supported by the observation that there is a small systematic error of approximately 3 mm in the mean AP (Up-Down) direction [Table III (a)]. In this context, the BAT might even be expected to cause an increase in observed toxicity, but this was not found in the current investigation, which found that the toxicity rates were roughly similar between the BAT and no-BAT groups. Despite there being the possibility that small systematic errors may be introduced, the BAT has been demonstrated to permit the correction of large errors, and this may be the major mechanism of action when influencing toxicity outcomes. Finally, one additional alternative explanation to the observed results is the longer follow-up in the no-BAT group, and consequent longer period for measuring toxicity events in this group.
The authors recognize the biases and limitations of a retrospective review. Also, the results of the BAT on late GI and GU toxicity should be compared prospectively against or in combination with other techniques, such as rectal balloons, fiducials, and adaptive radiotherapy techniques. Our study is unique in that both BAT and no-BAT groups had virtually the same patient, disease, and treatment factors -however, these factors were all specific to our patient population and treatment facilities. The results reported herein must be validated using similar comparisons at other institutions whose target volume, prescription dose, IMRT treatment planning, and delivery systems are different than ours. Further efforts are necessary to more adequately explore the role of the BAT in influencing late RT toxicity -ideally such analyses would be done prospectively and in a multi-institutional setting.
